In contrast to the 2 at present authorised vaccines, J&J’sdoes not require a second shot or must be shipped frozen.
Johnson & Johnson mentioned on Thursday it has requested U.S. well being regulators to authorize its single-dose COVID-19 vaccine for emergency use.
The drugmaker’s utility to the U.S. Meals and Drug Administration (FDA) follows its Jan. 29 report by which it mentioned the vaccine had a 66% fee of stopping infections in its massive international trial.
Additionally learn: EU approves Pfizer-BioNTech coronavirus vaccine
J&J’s single-shot vaccine may assist enhance provide and simplify the U.S. immunization marketing campaign, amid considerations of contemporary surges because of the extra contagious UK coronavirus variant and the potential of decrease vaccine efficacy in opposition to the variant that first emerged in South Africa.
In contrast to the 2 at present authorised vaccines from PfizerInc/BioNTech SE and Moderna Inc, J&J’sdoes not require a second shot or must be shipped frozen.
After the corporate’s utility, regulators will want time to analyse the information and an advisory committee might want to meet. The corporate’s chief scientific officer mentioned final month J&J was on observe to roll out the vaccine in March.
Shares of Johnson & Johnson, Moderna and Pfizer have been little modified in after-hours commerce.
America has an settlement to purchase 100 million doses of J&J’s vaccine for $1 billion, and the choice of buying a further 200 million doses.
The corporate has mentioned it has doses prepared for supply upon emergency approval. It goals to ship 1 billion doses in 2021with manufacturing in the US, Europe, South Africa and India.